Research programme: chimeric antigen receptor macrophages - Carisma Therapeutics

Drug Profile

Research programme: chimeric antigen receptor macrophages - Carisma Therapeutics

Alternative Names: CAR Macrophage Cellular Immunotherapy - Carisma Therapeutics; CARMA 0508

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pennsylvania
  • Developer Carisma Therapeutics
  • Class Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 27 Jun 2018 CARMA Therapeutics is now called Carisma Therapeutics
  • 27 Jun 2018 Carisma Therapeutics plans clinical development in Solid tumours in 2019
  • 13 Jun 2017 Preclinical trials in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top